Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1979 8
1980 48
1981 85
1982 178
1983 229
1984 229
1985 259
1986 265
1987 298
1988 363
1989 376
1990 321
1991 390
1992 416
1993 442
1994 497
1995 523
1996 631
1997 584
1998 576
1999 568
2000 533
2001 547
2002 570
2003 535
2004 539
2005 513
2006 503
2007 535
2008 573
2009 557
2010 581
2011 587
2012 615
2013 594
2014 578
2015 542
2016 595
2017 534
2018 540
2019 551
2020 563
2021 436
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

18,307 results
Results by year
Filters applied: . Clear all
Page 1
History, pharmacokinetics, and pharmacology of acyclovir.
King DH. King DH. J Am Acad Dermatol. 1988 Jan;18(1 Pt 2):176-9. doi: 10.1016/s0190-9622(88)70022-5. J Am Acad Dermatol. 1988. PMID: 2828440
Acyclovir triphosphate inactivates viral deoxyribonucleic acid polymerase. Acyclovir incorporation into the growing viral deoxyribonucleic acid chain causes its termination. ...
Acyclovir triphosphate inactivates viral deoxyribonucleic acid polymerase. Acyclovir incorporation into the growing viral deox
Chickenpox: treatment.
Cohen J, Breuer J. Cohen J, et al. BMJ Clin Evid. 2015 Jun 15;2015:0912. BMJ Clin Evid. 2015. PMID: 26077272 Free PMC article. Review.
CONCLUSIONS: In this systematic overview we present information relating to the effectiveness and safety of aciclovir, within 24 hours of onset of rash or later than 24 hours of onset of rash, in otherwise-healthy adults and children (including neonates); and aciclovir
CONCLUSIONS: In this systematic overview we present information relating to the effectiveness and safety of aciclovir, within 24 hour …
Acyclovir. A review of its pharmacodynamic properties and therapeutic efficacy.
Richards DM, Carmine AA, Brogden RN, Heel RC, Speight TM, Avery GS. Richards DM, et al. Drugs. 1983 Nov;26(5):378-438. doi: 10.2165/00003495-198326050-00002. Drugs. 1983. PMID: 6315332 Review.
Acyclovir (aciclovir) is a nucleoside analogue antiviral drug related to cytarabine, idoxuridine, trifluridine and vidarabine. ...Acyclovir ointment demonstrated little benefit in recurrent genital herpes but topical acyclovir cream decreased the cours
Acyclovir (aciclovir) is a nucleoside analogue antiviral drug related to cytarabine, idoxuridine, trifluridine and vidarabine.
Valacyclovir.
Acosta EP, Fletcher CV. Acosta EP, et al. Ann Pharmacother. 1997 Feb;31(2):185-91. doi: 10.1177/106002809703100211. Ann Pharmacother. 1997. PMID: 9034421 Review.
Valacyclovir is rapidly and almost completely hydrolyzed to acyclovir prior to systemic exposure. The bioavailability of valacyclovir is 54% compared to approximately 20% for oral acyclovir. ...CONCLUSIONS: Valacyclovir has improved bioavailability over acyclovir
Valacyclovir is rapidly and almost completely hydrolyzed to acyclovir prior to systemic exposure. The bioavailability of valacyclovir …
[Acyclovir].
Mohr K. Mohr K. Dtsch Med Wochenschr. 1993 Dec 10;118(49):1817-8. doi: 10.1055/s-0029-1235271. Dtsch Med Wochenschr. 1993. PMID: 8253046 German. No abstract available.
Acyclovir.
Zabrosky CA, Milkovich G. Zabrosky CA, et al. Infect Control. 1986 Apr;7(4):228-9. doi: 10.1017/s0195941700084009. Infect Control. 1986. PMID: 3634762 No abstract available.
Acyclovir.
Laskin OL. Laskin OL. Ration Drug Ther. 1984 May;18(5):1-6. Ration Drug Ther. 1984. PMID: 6096924 No abstract available.
Acute kidney injury (AKI) associated with intravenous aciclovir in adults: Incidence and risk factors in clinical practice.
Ryan L, Heed A, Foster J, Valappil M, Schmid ML, Duncan CJA. Ryan L, et al. Int J Infect Dis. 2018 Sep;74:97-99. doi: 10.1016/j.ijid.2018.07.002. Epub 2018 Jul 7. Int J Infect Dis. 2018. PMID: 30048817 Free article.
In univariate analysis, AKI occurred more frequently in patients with pre-existing chronic kidney disease (CKD), diabetes, and in patients treated with higher daily doses of aciclovir. There was also a trend to increased age in patients with AKI. ...CONCLUSIONS: AKI is an …
In univariate analysis, AKI occurred more frequently in patients with pre-existing chronic kidney disease (CKD), diabetes, and in patients t …
Aciclovir-induced acute kidney injury.
Coscojuela Otto A, Peña Porta JM, Álvarez Lipe R. Coscojuela Otto A, et al. Med Clin (Barc). 2020 Jan 10;154(1):36. doi: 10.1016/j.medcli.2019.03.031. Epub 2019 May 31. Med Clin (Barc). 2020. PMID: 31160042 English, Spanish. No abstract available.
Acyclovir delivery systems.
Cortesi R, Esposito E. Cortesi R, et al. Expert Opin Drug Deliv. 2008 Nov;5(11):1217-30. doi: 10.1517/17425240802450340. Expert Opin Drug Deliv. 2008. PMID: 18976132 Review.
Although the development of successful antiviral agents against infections caused by herpes viruses had been slow until the last decade, the production of delivery systems for acyclovir are a promising alternative. The present review summarizes the principal advances made …
Although the development of successful antiviral agents against infections caused by herpes viruses had been slow until the last decade, the …
18,307 results
You have reached the last available page of results. Please see the User Guide for more information.